Search | Clinical Trials Finder

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GFF MDI (PT003), GP MDI (PT001), FF MDI (PT005), Placebo; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 113
States / cities: Birmingham, Alabama • Florence, Alabama • Jasper, Alabama + 110 more

Conditions: Severe Asthma
Interventions: Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more

Conditions: Chronic Obstructive Pulmonary Disorder
Interventions: BFF MDI (PT009) 320/9.6 μg, BFF MDI (PT009) 160/9.6 μg, FF MDI (PT005) 9.6 μg; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 121
States / cities: Dothan, Alabama • Huntsville, Alabama • Sheffield, Alabama + 107 more

Conditions: Asthma
Interventions: formoterol, Dry Powder Inhaler (Twisthaler); Drug · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: COPD
Interventions: BGF MDI 320/14.4/9.6 μg, GFF MDI (PT003) 14.4/9.6 μg, BFF MDI (PT009) 320/9.6 μg, Symbicort® Turbuhaler® (TBH) Inhalation Powder; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 63
States / cities: Andalusia, Alabama • Jasper, Alabama • Peoria, Arizona + 54 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 2,103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 121
States / cities: Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more

Conditions: Healthy Participants
Interventions: Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Asthma
Interventions: Symbicort, Budesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 31
States / cities: Huntington Beach, California • Long Beach, California • Los Angeles, California + 28 more

Conditions: Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions: arformoterol, Salmeterol; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 90
States / cities: Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 77 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Aclidinium/formoterol 400/12μg, Formoterol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: COPD
Interventions: PT010 Dose 1, PT010 Dose 2, Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COPD
Interventions: BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BFF MDI 320/9.6 μg; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 64
States / cities: Dothan, Alabama • Jasper, Alabama • Peoria, Arizona + 56 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Asthma
Interventions: Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10, Placebo; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 47
States / cities: Pell City, Alabama • Scottsdale, Arizona • Cypress, California + 42 more

Conditions: COPD
Interventions: Racemic formoterol, Arformoterol tartrate inhalation solution; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 6
States / cities: Long Beach, California • Fort Lauderdale, Florida • Raleigh, North Carolina + 3 more

Conditions: Asthma
Interventions: tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF; Drug
Lead sponsor: Novartis; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more

Conditions: Asthma
Interventions: Fluticasone propionate/Formoterol Fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 29
States / cities: Birmingham, Alabama • Mission Viejo, California • Orange, California + 26 more

Conditions: Asthma
Interventions: Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Asthma
Interventions: Beclomethasone Dipropionate/Formoterol Fumarate, Beclomethasone Dipropionate; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 91
States / cities: Mobile, Alabama • Chandler, Arizona • Encinitas, California + 65 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Budesonide/formoterol pMDI, Budesonide pMDI, Formoterol Turbuhaler; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 143
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 140 more

Conditions: Asthma
Interventions: FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg, Placebo; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 19
States / cities: Phoenix, Arizona • Anaheim, California • Long Beach, California + 16 more

Conditions: Asthma
Interventions: Budesonide/formoterol pMDI, Budesonide HFA pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 46
States / cities: Muscle Shoals, Alabama • Little Rock, Arkansas • Anaheim, California + 43 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Budesonide/formoterol pMDI, Formoterol Turbuhaler; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 131
States / cities: Birmingham, Alabama • Huntsville, Alabama • Jasper, Alabama + 128 more

Search by objective public record fields.

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Randomized, Crossover Safety and Pharmacokinetics Study of PT010

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

VENTURI (VENTilation Using Respiratory Imaging)

A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD